Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $15.00 price target on ORIC Pharmaceuticals (NASDAQ: ORIC)The analyst comments: "ORIC ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE